HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 17/Aug 00:00
Vimgreen Pharma completes enrollment in phase 2 trial of VG081821AC to treat Parkinson's disease
Vimgreen Pharmaceuticals, a science─driven pharmaceutical company focused on the modulation of adenosine signalling, announced the completion of enrollment of its phase 2 clinical trial of VG081821AC, a
Articles similaires
Ocugen completes dosing in subjects with Stargardt disease in high dose cohort of phase 1/2 GARDian trial of OCU410ST, a modifier gene therapy
pharmabiz.com - 29/Aug 00:00
Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced...
First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
drugs.com - 05/Sep 04:09
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML
drugs.com - 06/Sep 07:09
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
haei.org - 06/Sep 18:54
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
Collegium Pharma acquires Ironshore Therapeutics
pharmabiz.com - 06/Sep 00:00
Collegium Pharmaceutical Inc, a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious...
Nxera Pharma to get US$ 35 mn from Neurocrine for successful completion of phase 2 trial with NBI─1117568 in adults with schizophrenia
pharmabiz.com - 03/Sep 00:00
Nxera Pharma Co., Ltd.(formerly known as Sosei Group or Sosei Heptares), announces that it will receive a US$ 35 million payment from Neurocrine...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Les derniers communiqués
-
Aucun élément